Clinical trials: HSV
HSV Infection
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg…
- Trial name
- PRIOH-1 (NCT03073967)
- Testing
- Pritelivir, Investigator's choice
- Where
- 70 sites in United States, Argentina and 13 more
- Volunteers
- 158 people
- Sponsor
- AiCuris Anti-infective Cures AG
HSV
Evaluating Benzoyl Peroxide for Preventing Recurrence of HSV-1 Outbreaks With Rescue Crossover Option
Here's a clear, concise, and accurate brief summary suitable for your ClinicalTrials.gov PRS submission: Brief Summary: This randomized, double-blind, placebo-controlled clinical trial evaluates the effectiveness of topical…
- Trial name
- NCT07032649
- Testing
- Benzoyl Peroxide 10% Bar
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Greg Bew
HSV
Expanded Access Intermediate Size Treatment Protocol: Pritelivir for Immunocompromised Subjects with Treatment Resistant Herpes Simplex Virus Type 1 or 2
AiCuris Anti-infective Cures AG (AiCuris) is developing pritelivir for the oral treatment of acyclovir-resistant (ACV-R) mucocutaneous herpes simplex virus (HSV) infections in immunocompromised subjects.
- Trial name
- NCT05844436
- Testing
- Pritelivir
- Sponsor
- AiCuris Anti-infective Cures AG
HSV-2 Infection, Herpes Simplex Virus Infection
NOWDx Test for the Diagnosis of Herpes Simplex Virus Type 2
This study is designed to compare the performance of the NOWDx HSV-2 Test to a currently marketed device. The intent is to show the rapid test device is comparable to the currently marketed device.
- Trial name
- NCT04294030
- Testing
- Diagnostic Test: NOWDx HSV-2 Test
- Where
- 3 sites in United States
- Sponsor
- NOWDiagnostics, Inc.
HSV Infection
Potential Influence of Esomeprazole on the Pharmacokinetics of Pritelivir
To investigate the effect of esomeprazole (ESO) on the pharmacokinetics of pritelivir (PTV), and to investigate the safety and tolerability of PTV.
- Trial name
- NCT05513625
- Testing
- Pritelivir, ESO and pritelivir
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AiCuris Anti-infective Cures AG
HSV Infection
Efficacy of Lazolex® Gel in the Treatment of Herpes Simplex
Study aimed to evaluate the efficacy and tolerance of Lazolex®, an emollient gel, to treat mucocutaneous lesions caused by herpes simplex virus.
- Trial name
- NCT06089252
- Testing
- walnut extract
- Volunteers
- 30 people
- Sponsor
- Iveriapharma LLC
HSV-2
Safety and Efficacy Study for a New Antiviral Drug to Treat Genital Herpes Type 2
The aim of the study is to find out whether AIC316 is safe and efficacious for the prevention of reactivation of genital herpes
- Trial name
- NCT01047540
- Testing
- AIC316
- Where
- 6 sites in United States
- Volunteers
- 156 people
- Sponsor
- AiCuris Anti-infective Cures AG
HSV, Herpes Labialis
Immune Response and General Immune Health in Subjects Infected With Herpes Simplex Virus Type 1 (HSV-1)
Subjects were recruited who were positive for antibody against herpes simplex virus type 1 (HSV-1) and self-reported having in the previous 12 months 6 or more herpes labialis outbreaks (group A), 1 or 2 outbreaks (group B), or…
- Trial name
- NCT03661541
- Testing
- Squaric Acid Dibutyl Ester
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Squarex, LLC
Herpes Labialis, HSV
A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis
Primary Objective: To assess local and generalized adverse events with repeat topical application of 2% and 0.5% squaric acid dibutyl ester (SADBE) in subjects with frequent herpes labialis (4 or more episodes in the previous 12…
- Trial name
- NCT03521479
- Testing
- Squaric Acid Dibutyl Ester
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Squarex, LLC
HSV-2 Infection, Genital Herpes
The VIBLOK SAfety and perFormancE Trial
Genital herpes has a high prevalence in industrialized as well as developing countries. Genital herpes causes genital ulcers, increases risk for acquiring HIV infection, and may be transmitted mother to child during birth with…
- Trial name
- SAFE (NCT03080961)
- Testing
- VIBLOK barrier cream
- Where
- 3 sites in Netherlands
- Volunteers
- 82 people
- Sponsor
- CLJI Worldwide
Genital Herpes, HSV-2 Infection
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence.
- Trial name
- NCT03146403
- Testing
- GEN-003, Matrix-M2, 0.9% normal saline
- Where
- 8 sites in United States
- Volunteers
- 33 people
- Sponsor
- Genocea Biosciences, Inc.
HIV Infections, HSV-2 Genital Herpes
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing.
To assess the retention and anti-viral activity (human immunodeficiency virus (HIV) and herpes simplex virus 2 (genital herpes, HSV-2) of SPL7013 in cervicovaginal samples taken up to 24 hours after administration of 3% SPL7013…
- Trial name
- NCT00740584
- Testing
- 3% SPL7013 Gel (VivaGel)
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Starpharma Pty Ltd
HSV-2
A Safety Study to Assess a DNA Vaccine Administered by Particle Mediated Delivery to the Skin in Healthy Subjects
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing.
- Trial name
- NCT00310271
- Testing
- pPJV7630 with pPJV2012 administered by PMED
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- PowderMed
HSV-2
Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing.
- Trial name
- NCT00274300
- Testing
- pPJV7630 administered by PMED
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- PowderMed